BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET ...Middle East

PR Newswire - News
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy BerGenBio to confirm the ACCORD2 data by progressing...

Hence then, the article about bergenbio announces complete data analysis of accord2 phase ii bemcentinib study in hospitalized covid 19 patients primary efficacy endpoint met was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET )

Apple Storegoogle play

Last updated :

Also on site :